Generic Name and Formulations:
Pegaspargase 750 IU/mL; soln for IV or IM inj; preservative-free.
Shire US, Inc.
Indications for ONCASPAR:
First-line acute lymphoblastic leukemia (including patients with asparaginase hypersensitivity).
Adults and Children:
Give by IV inj over 1–2hrs or by IM inj (max 2mL/inj site). 2500 IU/m2 no more frequently than every 14 days.
History of pancreatitis, serious hemorrhage, or thrombosis with prior L-asparaginase therapy.
Have resuscitation equipment available and observe patient for 1hr post-dose. Monitor serum glucose, coagulation parameters. Discontinue if serious allergic reactions, thrombotic events, or pancreatitis occur. Monitor for hepatotoxicity and abnormal liver function. Pregnancy (Cat.C). Nursing mothers: not recommended.
Allergic reactions (including anaphylaxis), hyperglycemia, pancreatitis, CNS thrombosis, coagulopathy, hyperbilirubinemia, elevated transaminases, hyperlipidemia.
Single-use vial (5mL)—1
Neurology Advisor Articles
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- New 15-Item Dyspnea-ALS-Score Assesses Dyspnea in ALS
- CDC: About One in Five U.S. Adults Have Chronic Pain
- Fingolimod Cuts Multiple Sclerosis Relapses in Pediatric Patients
- Gains in Insurance Coverage Seen for Lesbian, Gay, Bisexual Adults
- Brivaracetam Effective for Reducing Seizures in Patients with Epileptic Encephalopathies